Table 1 Expression of THEM6 in breast cancer and its correlation with clinicopathological features.
From: THEM6 is a prognostic biomarker for breast cancer and is associated with immune infiltration
Characteristic | THEM6 expression | p value | ||
|---|---|---|---|---|
Low (N = 47) | High (N = 47) | Total (N = 94) | ||
Age at surgery | 1 | |||
 ≥ 50 | 27 (28.72%) | 28 (29.79%) | 55 (58.51%) |  |
 < 50 | 20 (21.28%) | 19 (20.21%) | 39 (41.49%) |  |
Ki-67 | 0.01 | |||
 ≥ 20% | 22 (23.40%) | 35 (37.23%) | 57 (60.64%) |  |
 < 20% | 25 (26.60%) | 12 (12.77%) | 37 (39.36%) |  |
Subtypes | 0.000069 | |||
 Benign tumor | 14 (14.89%) | 0 (0.0e + 0%) | 14 (14.89%) |  |
 Her2+ | 3 (3.19%) | 7 (7.45%) | 10 (10.64%) |  |
 LuminalA | 5 (5.32%) | 5 (5.32%) | 10 (10.64%) |  |
 LuminalB | 8 (8.51%) | 2 (2.13%) | 10 (10.64%) |  |
 TNBC | 17 (18.09%) | 33 (35.11%) | 50 (53.19%) |  |
Tumor stage | 0.00015 | |||
 Tis | 17 (18.09%) | 2 (2.13%) | 19 (20.21%) |  |
 T1 | 10 (10.64%) | 21 (22.34%) | 31 (32.98%) |  |
 T2 | 19 (20.21%) | 19 (20.21%) | 38 (40.43%) |  |
 T3 | 1 (1.06%) | 5 (5.32%) | 6 (6.38%) |  |
AJCC TNM stage | 0.0014 | |||
 Stage 0 | 17 (18.09%) | 2 (2.13%) | 19 (20.21%) |  |
 Stage I | 9 (9.57%) | 15 (15.96%) | 24 (25.53%) |  |
 Stage II | 18 (19.15%) | 23 (24.47%) | 41 (43.62%) |  |
 Stage III | 3 (3.19%) | 7 (7.45%) | 10 (10.64%) |  |
Neural invasion | 0.71 | |||
 No known involvement | 44 (46.81%) | 42 (44.68%) | 86 (91.49%) |  |
 Pathologically positive | 3 (3.19%) | 5 (5.32%) | 8 (8.51%) |  |
Vessel invasion | 0.26 | |||
 No known involvement | 39 (43.82%) | 33 (37.08%) | 72 (80.90%) |  |
 Pathologically positive | 6 (6.74%) | 11 (12.36%) | 17 (19.10%) |  |
